V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20215048 | 20081243 | 1.78 | 77.5 | Palliative (P) | 2016-06-19 | 2016-06-26 | GO2 TRIAL | 01 | N | TRIAL | 101416336 |
| 20215049 | 20081244 | 1.83 | 64.5 | Disease modification (D) | 2018-09-14 | 2018-09-21 | Cape+Cisplatin+Trastuzumab Load | 02 | N | IMATINIB | 101655671 |
| 20215050 | 20081245 | 1.6 | 75.5 | Palliative (P) | 2019-07-27 | 2019-07-27 | Trial Unspecified | 01 | N | TRIAL | 100159587 |
| 20215051 | 20081246 | 1.78 | 85.6 | Curative (C) | 2016-03-02 | 2016-04-01 | Fluorouracil+Mitomycin+RT (Anal Ca) | 02 | N | FLUOROURACIL + MITOMYCIN + RT | 100625264 |
| 20215052 | 20081247 | 1.77 | 47.5 | Palliative (P) | 2015-09-09 | 2015-09-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101748537 |
| 20215053 | 20081248 | 1.83 | 68.8 | Curative (C) | 2020-03-27 | 2020-03-28 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100815574 |
| 20215054 | 20081249 | 1.68 | 70.7 | null | 2018-09-07 | 2018-09-20 | Cape+Cisplatin+Trastuzumab Load | 02 | null | IMATINIB | 101816778 |
| 20215057 | 20081250 | 1.8 | null | 03 | 2019-04-30 | 2019-04-30 | IMATINIB | 02 | N | IMATINIB | 101180524 |
| 20215058 | 20081251 | 1.66 | 71.8 | Curative (C) | 2016-06-23 | 2016-07-25 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100328862 |
| 20215059 | 20081252 | 1.6 | 103.3 | null | 2018-10-21 | 2018-10-21 | LANREOTIDE | 02 | N | LANREOTIDE | 100114699 |
| 20215060 | 20081253 | 1.61 | 54 | Palliative (P) | 2019-07-11 | 2019-07-12 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101185904 |
| 20215061 | 20081254 | null | null | null | 2019-03-27 | 2019-03-31 | LANREOTIDE | 02 | null | LANREOTIDE | 100336048 |
| 20215062 | 20081255 | 1.6 | 76.1 | Palliative (P) | 2016-07-07 | 2016-07-23 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101550124 |
| 20215063 | 20081256 | 1.8 | 83.2 | null | 2017-09-14 | 2017-09-16 | Imatinib 400mg | 02 | null | IMATINIB | 100228842 |
| 20215064 | 20081257 | 1.56 | 69.2 | Palliative (P) | 2016-11-20 | 2016-11-20 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100043285 |
| 20215066 | 20081258 | 1.6 | 51 | Curative (C) | 2016-07-05 | 2016-07-30 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 100416258 |
| 20215068 | 20081260 | 1.76 | 92.4 | Curative (C) | null | 2016-08-05 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100778076 |
| 20215070 | 20081261 | 1.59 | 46.7 | Palliative (P) | 2018-08-21 | 2018-08-30 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101541987 |
| 20215071 | 20081262 | null | 97 | Adjuvant (A) | null | 2015-02-23 | null | null | Y | TRIAL | 101475060 |
| 20215072 | 20081263 | null | null | Neo-adjuvant (N) | 2018-07-07 | 2018-07-09 | IMATINIB | N | N | IMATINIB | 100197979 |
| 20215075 | 20081265 | 1.75 | 0 | Palliative (P) | 2018-09-30 | 2018-10-19 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | LANREOTIDE | 100698053 |
| 20215076 | 20081266 | 1.75 | 68.7 | Not known (9) | 2017-07-14 | 2017-07-24 | Fluorouracil+Mitomycin+RT (Anal Ca) | null | N | FLUOROURACIL + MITOMYCIN + RT | 100048467 |
| 20215077 | 20081267 | null | null | Adjuvant (A) | 2018-03-27 | 2018-03-28 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100987567 |
| 20215079 | 20081269 | 1.68 | 64 | Curative (C) | 2018-09-21 | 2018-10-18 | FLUOROURACIL + MITOMYCIN + RT | 02 | null | FLUOROURACIL + MITOMYCIN + RT | 101431692 |
| 20215080 | 20081270 | 0 | 74.6 | Neo-adjuvant (N) | 2017-07-10 | 2017-07-11 | Imatinib 400mg | 02 | N | IMATINIB | 100493039 |
| 20215081 | 20081271 | 1.54 | 74 | Palliative (P) | 2019-07-08 | 2019-07-22 | HCX (Cape + Cisp + Tras) - Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100069703 |
| 20215082 | 20081272 | 1.81 | 88.8 | Palliative (P) | 2019-11-01 | 2019-11-14 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101651174 |
| 20215083 | 20081273 | 1.74 | 71.9 | Palliative (P) | 2019-12-09 | 2019-12-11 | CAPECITABINE + CISPLATIN + Trastuzumab | 02 | N | TRIAL | 101425702 |
| 20215084 | 20081274 | 1.8 | 76 | Palliative (P) | 2019-03-31 | 2019-04-08 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100017471 |
| 20215086 | 20081275 | 1.63 | 81.5 | Neo-adjuvant (N) | 2019-08-07 | 2019-09-16 | Trial Unspecified | 01 | N | TRIAL | 101474722 |
| 20215088 | 20081277 | 1.8 | 74.6 | Disease modification (D) | 2019-06-28 | 2019-07-16 | Trial Unspecified | 01 | N | TRIAL | 100769274 |
| 20215089 | 20081278 | 1.8 | 69.6 | Palliative (P) | 2020-07-17 | 2020-07-22 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 100671897 |
| 20215092 | 20081280 | 0 | 65.8 | Neo-adjuvant (N) | 2018-07-09 | 2018-07-09 | Imatinib 400mg | 02 | N | IMATINIB | 100146399 |
| 20215093 | 20081281 | 1.62 | 58 | Palliative (P) | 2018-06-24 | 2018-07-01 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101268712 |
| 20215097 | 20081284 | 1.7 | 83.2 | Neo-adjuvant (N) | 2016-12-06 | 2016-12-06 | IMATINIB | 02 | N | IMATINIB | 101284377 |
| 20215098 | 20081285 | 1.63 | 0 | Curative (C) | null | 2019-12-03 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 100080769 |
| 20215101 | 20081286 | 1.53 | 75.7 | Palliative (P) | 2017-04-03 | 2017-04-08 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101338233 |
| 20215103 | 20081287 | 1.75 | 85.1 | Adjuvant (A) | 2018-12-25 | 2019-01-17 | Cape+Cisplatin+Trastuzumab Main | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 101743810 |
| 20215104 | 20081288 | 1.79 | 58 | Neo-adjuvant (N) | 2018-05-08 | 2018-05-08 | Trial Unspecified | 1 | N | TRIAL | 101281938 |
| 20215106 | 20081290 | 1.81 | 87.1 | Curative (C) | 2018-11-08 | 2018-11-23 | FLUOROURACIL + MITOMYCIN + RT | N | Y | FLUOROURACIL + MITOMYCIN + RT | 101314334 |
| 20215107 | 20081291 | 1.85 | 66.8 | Curative (C) | 2018-12-12 | 2018-12-26 | Fluorouracil+Mitomycin+RT (Anal Ca) | N | Y | FLUOROURACIL + MITOMYCIN + RT | 100046321 |
| 20215108 | 20081292 | 1.68 | 71.4 | Palliative (P) | 2017-02-13 | 2017-02-17 | CETUXIMAB + IRINOTECAN + MDG | 02 | N | CETUXIMAB + FLUOROURACIL + IRINOTECAN | 101198685 |
| 20215109 | 20081293 | 1.74 | 52.1 | Curative (C) | null | 2019-12-29 | Fluorouracil+Mitomycin+RT (Anal Ca) | 2 | Y | FLUOROURACIL + MITOMYCIN + RT | 101705105 |
| 20215110 | 20081294 | 1.82 | 81.3 | Palliative (P) | 2017-08-10 | 2017-08-15 | Trial Unspecified | 1 | N | TRIAL | 101675178 |
| 20215111 | 20081295 | null | 64.5 | Palliative (P) | 2016-11-11 | 2016-11-12 | LANREOTIDE | 02 | N | LANREOTIDE | 100221423 |
| 20215112 | 20081296 | 1.6 | null | Adjuvant (A) | 2018-07-02 | 2018-07-02 | IMATINIB | 02 | N | IMATINIB | 100586489 |
| 20215113 | 20081297 | 1.7 | 58.1 | Palliative (P) | 2018-01-17 | 2018-01-17 | Cape+Cisplatin+Trastuzumab Load | 02 | N | TRIAL | 101129584 |
| 20215115 | 20081298 | 1.68 | 0 | Curative (C) | 2018-12-21 | 2019-01-05 | FLUOROURACIL + MITOMYCIN + RT | 02 | Y | FLUOROURACIL + MITOMYCIN + RT | 101210331 |
| 20215116 | 20081299 | 1.67 | 80.3 | Palliative (P) | 2019-09-25 | 2019-10-16 | Cape+Cisplatin+Trastuzumab Load | 02 | N | CAPECITABINE + CISPLATIN + TRASTUZUMAB | 100016941 |
| 20215117 | 20081300 | 0 | 81.8 | Neo-adjuvant (N) | 2019-09-18 | 2019-09-19 | IMATINIB | 02 | N | IMATINIB | 101362274 |